Literature DB >> 17212717

In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.

S Björkman1, A Folkesson, E Berntorp.   

Abstract

In vivo recovery (IVR) is traditionally used as a parameter to characterize the pharmacokinetic properties of coagulation factors. It has also been suggested that dosing of factor VIII (FVIII) and factor IX (FIX) can be adjusted according to the need of the individual patient, based on an individually determined IVR value. This approach, however, requires that the individual IVR value is more reliably representative for the patient than the mean value in the population, i.e. that there is less variance within than between the individuals. The aim of this investigation was to compare intra- and interindividual variance in IVR (as U dL1 per U kg1) for FVIII and plasma-derived FIX in a cohort of non-bleeding patients with haemophilia. The data were collected retrospectively from six clinical studies, yielding 297 IVR determinations in 50 patients with haemophilia A and 93 determinations in 13 patients with haemophilia B. For FVIII, the mean variance within patients exceeded the between-patient variance. Thus, an individually determined IVR value is apparently no more informative than an average, or population, value for the dosing of FVIII. There was no apparent relationship between IVR and age of the patient (1.5-67 years). For FIX, the mean variance within patients was lower than the between-patient variance, and there was a significant positive relationship between IVR and age (13-69 years). From these data, it seems probable that using an individual IVR confers little advantage in comparison to using an age-specific population mean value. Dose tailoring of coagulation factor treatment has been applied successfully after determination of the entire single-dose curve of FVIII:C or FIX:C in the patient and calculation of the relevant pharmacokinetic parameters. However, the findings presented here do not support the assumption that dosing of FVIII or FIX can be individualized on the basis of a clinically determined IVR value.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17212717     DOI: 10.1111/j.1365-2516.2006.01401.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  14 in total

Review 1.  Secondary prophylaxis with factor IX concentrates: continuous infusion.

Authors:  Massimo Morfini
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

2.  Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.

Authors:  H Agersø; H R Stennicke; H Pelzer; E N Olsen; E P Merricks; N A Defriess; T C Nichols; M Ezban
Journal:  Haemophilia       Date:  2012-07-20       Impact factor: 4.287

3.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Authors:  S Björkman; V S Blanchette; K Fischer; M Oh; G Spotts; P Schroth; S Fritsch; L Patrone; B M Ewenstein; P W Collins
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824

Review 4.  Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.

Authors:  Massimo Morfini; Stefano Gherardini
Journal:  Ther Adv Hematol       Date:  2018-06-05

5.  Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

Authors:  Sven Björkman; Anna Folkesson; Siv Jönsson
Journal:  Eur J Clin Pharmacol       Date:  2009-06-26       Impact factor: 2.953

6.  Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity.

Authors:  Jocelyn A Schroeder; Juan Chen; Yingyu Chen; Yuanhua Cai; Hongyin Yu; Jeremy G Mattson; Paul E Monahan; Qizhen Shi
Journal:  Blood Adv       Date:  2021-03-09

7.  Treatment of hemophilia B: focus on recombinant factor IX.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Cinzia Sissa; Carlo Bonfanti
Journal:  Biologics       Date:  2013-02-12

8.  F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

Authors:  Alessio Branchini; Massimo Morfini; Barbara Lunghi; Donata Belvini; Paolo Radossi; Loredana Bury; Maria Luisa Serino; Paola Giordano; Dorina Cultrera; Angelo Claudio Molinari; Mariasanta Napolitano; Elisabetta Bigagli; Giancarlo Castaman; Mirko Pinotti; Francesco Bernardi
Journal:  J Thromb Haemost       Date:  2021-10-24       Impact factor: 16.036

9.  Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

Authors:  Albert Farrugia; Declan Noone; Uwe Schlenkrich; Steffen Schlenkrich; Brian O'Mahony; Josephine Cassar
Journal:  J Blood Med       Date:  2015-06-15

Review 10.  Pediatric Dosing and Body Size in Biotherapeutics.

Authors:  Rong Shi; Hartmut Derendorf
Journal:  Pharmaceutics       Date:  2010-12-16       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.